On November 9, Pfizer announced on its official website that the mRNA new crown vaccine candidate BNT162b2 developed in cooperation with the German company BioNTech has proven to be more than 90% effective, far higher than the 50% required by the FDA. Analysis of vaccinated persons and placebo patients (a total of 94 confirmed cases of new coronary pneumonia) showed that the effective rate of the vaccine reached more than 90% 7 days after the vaccine was vaccinated twice at 21 days intervals, which means that Protection is available 28 days after starting the vaccination. BNT162b2 mainly targets the entire S protein of the virus. It obtained fast-track certification from the FDA in mid-July. It entered Phase III clinical trials on July 27 and has recruited 43,538 participants so far. As of November 8, 2020, 38,955 of the participants have received the second dose of candidate vaccine, covering patients of different races and backgrounds.
Pfizer said that clinical trials are continuing and it is expected to conduct a final analysis of 164 confirmed cases of COVID-19, and will also evaluate the efficacy of the second dose of vaccine 14 days after vaccination, as well as candidate vaccines in people who have been previously exposed to the COVID-19 environment. The potential to provide protection against severe COVID-19. In addition, the two companies also stated that they are working hard to prepare the necessary safety and production data to be submitted to the FDA to prove the safety and quality of the vaccine products produced, and are expected to produce up to 50 million doses worldwide by the end of 2020 Vaccines, up to 1.3 billion doses of vaccines will be produced by the end of 2021.